An imbalance in progenitor cell populations reflects tumour progression in breast cancer primary culture models
© Donatello et al; licensee BioMed Central Ltd. 2011
Received: 4 January 2011
Accepted: 26 April 2011
Published: 26 April 2011
Many factors influence breast cancer progression, including the ability of progenitor cells to sustain or increase net tumour cell numbers. Our aim was to define whether alterations in putative progenitor populations could predict clinicopathological factors of prognostic importance for cancer progression.
Primary cultures were established from human breast tumour and adjacent non-tumour tissue. Putative progenitor cell populations were isolated based on co-expression or concomitant absence of the epithelial and myoepithelial markers EPCAM and CALLA respectively.
Significant reductions in cellular senescence were observed in tumour versus non-tumour cultures, accompanied by a stepwise increase in proliferation:senescence ratios. A novel correlation between tumour aggressiveness and an imbalance of putative progenitor subpopulations was also observed. Specifically, an increased double-negative (DN) to double-positive (DP) ratio distinguished aggressive tumours of high grade, estrogen receptor-negativity or HER2-positivity. The DN:DP ratio was also higher in malignant MDA-MB-231 cells relative to non-tumourogenic MCF-10A cells. Ultrastructural analysis of the DN subpopulation in an invasive tumour culture revealed enrichment in lipofuscin bodies, markers of ageing or senescent cells.
Our results suggest that an imbalance in tumour progenitor subpopulations imbalances the functional relationship between proliferation and senescence, creating a microenvironment favouring tumour progression.
Breast cancer is a heterogeneous disease of considerable social and economic burden. Significant interest surrounds the question whether cancer stem/progenitor cells drive tumour formation [1, 2], however it remains to be understood if progenitor analysis has prognostic value in cancer patients. One approach towards interrogating this involves using patient tumour primary cultures to correlate in vitro data and clinicopathological information.
Breast progenitor cells are isolated based on expression of markers suggesting capabilities to generate cells of mixed myoepithelial and luminal epithelial lineages [3, 4]. Other methods involve isolation of cells positive for aldehyde dehydrogenase (ALDH) activity , or ultrastructural identification . Importantly, primary breast cultures retain progenitor/stem cell populations .
Using primary cultures from human breast tumour and non-tumour tissue, we sought to define correlations between progenitor cell numbers and clinicopathological or functional indicators of cancer aggressiveness. Our results demonstrate an imbalance between two putative progenitor cell populations in clinicopathologically-aggressive tumours, in conjunction with functional alterations promoting increased proliferation or reduced growth arrest. Taken together, full investigations of progenitor populations in relation to clinicopathological parameters could make an important contribution towards a better understanding of breast cancer progression.
Suppliers: trypsin-EDTA, penicillin/streptomycin, penicillin/streptomycin/neomycin, fungizone, Cyquant, X-gal, Alexa-Fluor antibodies (Invitrogen); soybean trypsin inhibitor, collagenase I, hyaluronidase 1-S, DMEM/Ham's F12, bovine insulin, peroxidase-labelled secondary antibodies (Sigma); HMEC, mammary epithelial growth medium (MEGM) kits, foetal bovine serum (FBS, Lonza); glutaraldehyde (Fluka); osmium tetroxide (Electron Microscopy Services). Antibody suppliers: actin, ESA and SMA (Sigma); cytokeratin-19, PE-conjugated CALLA, FITC-conjugated EPCAM, FITC- or PE-conjugated IgG controls (Dako); cytokeratin-18 (Abcam); cytokeratin-14 (Millipore); vimentin and p63 (BD Biosciences).
Breast primary cultures were generated from patient lumpectomy/mastectomy samples with informed consent as approved by the Medical Ethics committees of Beaumont Hospital and the Mater Misericordiae Hospital, in accordance with the Declaration of Helsinki. One piece each of tumour tissue and non-tumour margins (Additional file 1) were cultured as described . Tissues were incubated in 10X penicillin/streptomycin/neomycin, minced in DMEM/F12 containing 1X penicillin/streptomycin/neomycin, 10% FBS, 10 μg/ml insulin, 5 μg/ml fungizone, 100U/ml hyaluronidase 1-S, 200U/ml collagenase and rotated for 2 hours/37°C. Supernatants were pelleted, washed and cultured in MEGM. Occasional fibroblast contamination was removed by brief trypsinization (to remove fibroblasts but not underlying epithelial cells), and cultures containing >30% fibroblasts were discarded. In some experiments, primary human mammary epithelial cells (HMEC, Lonza) were cultured in MEGM.
Breast cell lines
MCF10A and MDA-MB-231 cells (ATCC) grown normally in DMEM-F12, 5% horse serum, 0.5 μg/ml hydrocortisone, 10 μg/ml insulin, 100 ng/ml cholera toxin, 20 ng/ml human recombinant EGF (MCF10A) or DMEM, 10% FBS, 2 mM L-glutamine(MDA-MB-231) were conditioned in MEGM for 2-3 weeks and used in flow cytometry experiments as controls for normal and tumourogenic phenotypes respectively.
Primary cells (5 × 103) were plated in triplicate and harvested after 0, 3 or 6 days. Cyquant solution was incubated on freeze-thawed cells (5 min), and emitted fluorescence detected at 520 nm on a Wallac plate-reader. Fluorescence readings of unknown samples were translated into cell numbers by referring to two separate fluorescence standard curves - one for non-tumour and one for tumour cultures- constructed from known cell numbers (Additional file 2). The slope of each proliferation graph was calculated from the linear regression line using the formula y = mx+c, where m = slope and c = y-intercept.
Senescence-associated β-galactosidase assays
Primary cells (5 × 104) were plated in duplicate, and stained for senescence-associated β-galactosidase activity . Three brightfield micrographs per condition were captured, and blue senescent cells expressed as a percentage of total cells/field.
Immunofluorescence staining for epithelial and myoepithelial markers
Primary cells (passage 1-2) grown in chamber slides were fixed in 3.7% paraformaldehyde and immunostained for epithelial (K19, K18, ESA) or myoepithelial (SMA, K14, VIM) markers using DAPI as a nuclear counter-stain. Primary antibodies were omitted in negative controls, and slides visualized on a Zeiss LSM510-meta confocal microscope.
SDS-PAGE and Western blotting
Confluent primary cultures were harvested in RIPA (20 mM Tris-HCl pH7.5, 150 mM NaCl, 5 mM EDTA, 1% Triton-X100) containing protease and phosphatase inhibitors. Lysates were dounced and 25 μg supernatant subjected to SDS-PAGE and Western blot analysis for K19, K18, VIM and p63.
FACS analysis of putative progenitor cell populations
Confluent passage 0 primary cells (T25 flask/condition) were trypsinized, blocked in human serum and co-incubated with FITC-conjugated mouse anti-human EPCAM and PE-conjugated mouse anti-human CALLA (4°C/30 min). Negative controls were unlabelled or single-stained with FITC-EPCAM, PE-CALLA, FITC-IgG or PE-IgG. Cells were analyzed on a Beckman Coulter Cyan-ADP and/or an Accuri-C6 flow cytometer. Cells were sorted into CALLA+/EPCAM+, CALLA+/EPCAM-, CALLA-/EPCAM- or CALLA-/EPCAM+ populations on a BD FACSAria cell sorter. Some passage 0 cells were analyzed for activity of the stem cell marker ALDH by Aldefluor assay . Briefly, 2 × 105 cells were resuspended in assay buffer and incubated with activated substrate or the negative control reagent before analysis.
Transmission electron microscopy (TEM)
Passage 0 primary cultures or HMECs were fixed with 2.5% glutaraldehyde, processed as described  and analyzed on a FEI-Tecnai transmission electron microscope. TEM was also performed on sorted DN subpopulations expanded in 24-well plates.
Calculations and statistics
Data are expressed as mean ± standard error of the mean. Non-tumour versus tumour results were compared using non-parametric tests and one-tailed unpaired t-tests. Population variances were first compared using Instat-3.3.6 to inform the choice of equal/unequal variance between populations. The proliferation:senescence ratio was calculated based upon the data shown in Figure 2B - the linear regression slopes of proliferation graphs and the percentages of senescent cells at the timepoint measured.
Primary breast cultures recapitulate the cellular balance of human breast
Ultrastructural and functional properties of breast primary cultures separate non-tumour and tumour primary cultures
We next investigated if morphological differences were accompanied by cell fate differences (Figure 2B). Proliferation abilities were assessed by Cyquant assay on 4 non-tumour cultures and 12 tumour cultures - 5 low grade (LG, grade 1-2) and 7 high grade (HG, grade 3). Values were calculated relative to a standard curve of fluorescence intensity versus known cell numbers (Additional file 2). A significant increase in proliferation was observed in high grade tumour cultures (HG; grade 3) relative to non-tumour or low grade tumour cultures (LG; grades 1-2; Figure 2B, left). Since Cyquant proliferation assays quantify all cells rather than just actively-proliferating cells, we performed senescence-associated (SA) β-galactosidase assays  to estimate growth arrest (Figure 2B, right). Non-tumour cultures had two-fold higher SA-β-galactosidase staining than that in tumour cultures. This was independent of the grade of the originating tumour, and did not reflect an impaired capacity to senesce in response to exogenous stimulation (data not shown).
Increased proliferation:senescence ratios correlate with tumour progression
Non-tumour (P n = 4; S n = 4)
Low-grade tumours (P n = 5; S n = 4)
High-grade tumours (P n = 7, S n = 8)
Alterations in putative progenitor cell subpopulations correlate with aggressive tumours
Given DN differences in aggressive HG or ER-negative tumours versus aggressive HER2-positive tumours, we performed ultrastructural analysis on DN populations from one non-tumour and one tumour culture (grade 2 IDC, ER+, HER2+). Although both populations had many similarities (data not shown), unique to the tumour DN population was the presence of abundant lipofuscin bodies (Figure 4B, arrows). These markers of cellular ageing were also observed in unsorted normal and pre-invasive tumour cultures (data not shown).
Since both DN and DP populations are putative progenitor/stem cells [3, 4], we questioned whether population ratios better reflected tumour progression than changes in single populations (Figure 4C). Increased DN:DP ratios were observed in all aggressive tumour cultures (HG, ER- or HER2+) relative to non-tumour or non-aggressive tumour cultures. A DN:DP increase was also noted in metastatic MDA-MB-231 cells versus normal MCF-10A cells (Figure 4D). For these experiments, MDA-MB-231 and MCF-10A cells were switched from their normal media and conditioned to grow in MEGM (as used for primary cultures). Although this was not their preferred medium, the cells grew well and we did not observe any morphological differences as a result of media switching (Additional file 3). We also analyzed ALDH activity to estimate progenitor cell numbers. A low percentage of cells were ALDH-positive (Figure 4E, left). However ALDH activity in LG tumour cultures was significantly higher than that in non-tumour cultures (Figure 4E, right). Interestingly, ALDH activity dropped significantly from LG to HG cultures, to lower than that in non-tumour cultures (p < 0.001). This mirrored observed reductions in both DP and DN populations in HG versus LG tumour cultures (Figure 4A).
Intriguing recent work has suggested that immunohistochemical profiling of breast tumours for cancer stem cell populations may have prognostic value . To probe at a cellular level the relationship between progenitor cells and clinicopathological indicators of breast cancer progression, we isolated primary cells from tumour and non-tumour tissue and cultured them in serum-free medium . Although many isolation methods and media formulations have been described over the years, we chose this method because it allowed us a high yield of cells from small tissue samples and because the commercially-available medium offered advantages of consistency and reproducibility relative to self-made medium. Using these culture conditions, most cultures presented two cell-type populations as described [7, 15, 16], namely large and small polygonal cells which are presumptive epithelial and myoepithelial cells respectively. A relatively crude isolation approach which allows retention of multiple cellular populations may offer advantages over isolation approaches in which cells are purified to homogeneity, since a mixed cell population better recapitulates the cellular balance of tumours in vivo.
Myoepithelial marker expression was found to dominate over luminal epithelial expression, consistent with observations in HMEC [17, 18]. Expression studies have linked myoepithelial and mesenchymal/basal-like phenotypes; the latter associated with poor patient prognosis . While some studies favour separate media formulations , our ultrastructural data suggested that MEGM supported separate growth of non-tumour and tumour populations. For example, malignant characteristics including abnormal vesiculation, branched mitochondria, poorly-developed RER and multi-nucleation were observed only in tumour cultures.
Mesenchymal/basal-like phenotypes also promote progenitor growth and tissue regeneration . The expression of the myoepithelial marker p63 was recently described to be involved in the development of stratified epithelial tissue such as that of the breast, and it has been associated with the presence of progenitor cells and tumour progression . Interestingly, most of our non-tumour cultures expressed the luminal epithelial marker K19, but low levels of the myoepithelial (and progenitor) marker p63, while tumour cultures conversely expressed low levels of K19 and high levels of p63. These data may suggest that non-tumour cultures are enriched in more differentiated cells (K19-positive) than tumour cultures which may be less differentiated and more enriched in multipotent or non-specialized cells (p63-positive) . While K14/K18 are generic markers for discerning epithelial versus myoepithelial cells, K19/p63 are considered to discriminate more differentiated/specialized cells versus non differentiated/specialized cells [11, 18, 23]. In addition, CALLA/EPCAM have been described to better detect progenitor populations . In fact, we used CALLA and EPCAM as myoepithelial and epithelial markers to subdivide cultures into terminally-differentiated or undifferentiated (putative progenitor) populations. Both populations, double positive (DP) and double-negative (DN) for these markers have been described as putative progenitor cells [3, 4]. Our cultures had large DN populations and highest expression of myoepithelial markers, in accordance with other reports .
We sought to correlate subpopulation changes with tumour clinicopathological parameters, and observed decreased DP populations in aggressive tumours of high grade or ER negativity. ALDH activity was also reduced in HG tumours, an interesting fact since ALDH expression has been correlated with poor prognosis in breast cancer [5, 24] - although the opposite has been reported in ovarian cancer . However we did observe increased ALDH activity in LG tumours relative to non-tumour cultures. Taken together, our results could suggest that DP, DN and ALDH-positive populations are progenitor cells lost from aggressive HG or ER-negative tumours. Perhaps such progenitor cells generate fully-differentiated cells in normal tissue, and their loss could favour undifferentiated phenotypes in aggressive tumours. The DN population was also lower in aggressive HG or ER-negative tumours, but not in aggressive HER2-positive tumours. If individual cells over-expressing HER2 are indeed tumour-initiators , our DN results could represent a progenitor population associating with HER2 expression.
DN and DP populations have been described as slightly different putative progenitor/stem cell populations; with DN representing an undifferentiated population while DP represents a multipotent population [4, 12]. Since in normal tissue the balance between these 2 populations is tightly regulated, we wondered if the balance is disrupted in malignant phenotypes and may be a marker of tumour progression. Thus in an attempt to mathematically reflect this balance, we calculated the ratios between DN and DP subpopulations. Importantly, we show that a DN/DP imbalance (in the form of increased DN:DP ratios) identifies all three types of aggressive tumour, namely HG, ER-negative or HER2-positive. The abundance of lipofuscin bodies, markers of cellular ageing, in tumour DN populations is an interesting point. Since premature senescence was reduced in tumour versus non-tumour cultures, we speculate that tumour DN populations represent undifferentiated cells capable of senescing, and that DN reductions in aggressive HG or ER-negative tumours suggest loss of an endogenous tumour-suppressive mechanism.
Interestingly, we did not observe DN reductions in HER2-positive cultures. However elevated HER2 can drive premature senescence , and high DN:DP ratios better identify aggressive tumours than DN changes alone. Thus loss of a putative pro-senescence (DN) "normal" population is unlikely to drive tumour progression unless proliferation is high. Any pro-senescence (anti-tumourogenic) effects of HER2 could be outweighed by the pro-proliferative effects of HER2 . Our study has illustrated a stepwise increase in proliferation:senescence ratios through non-tumour, LG and HG tumours. The proliferation:senescence balance is an important determinant of tumour progression, dormancy or regression. If the DN:DP ratio estimates this, it could have prognostic value. Although progenitor isolation using markers will never recapitulate the complexity of these plastic and diverse cellular populations, our study nonetheless illustrates that marker studies can yield important insights into clinical samples.
mammary epithelial growth medium
human mammary epithelial cells
ductal carcinoma in situ
invasive ductal carcinoma
invasive tubular lobular carcinoma
smooth muscle actin
common acute lymphoblastic leukaemia antigen
epithelial cell adhesion molecule
CALLA & EPCAM double-positive
CALLA & EPCAM double-negative
transmission electron microscopy
The authors thank Cancer Research Ireland (CRI05HOP/AMH), the Irish Research Council for Science, Engineering & Technology (EMBARK/SD), Ministerio de Educación y Ciencia (IA), the Mater Foundation and the Beaumont Hospital Cancer Research & Development Trust. The confocal microscope was supported through the National Biophotonics and Imaging Platform, Ireland, and funded by the Irish Government's Programme for Research in Third Level Institutions, Cycle 4, Ireland's EU Structural Funds Programmes 2007 - 2013.
- Molyneux G, Geyer FC, Magnay FA, McCarthy A, Kendrick H, Natrajan R, Mackay A, Grigoriadis A, Tutt A, Ashworth A: BRCA1 basal-like breast cancers originate from luminal epithelial progenitors and not from basal stem cells. Cell Stem Cell. 7: 403-417.
- Kakarala M, Wicha MS: Implications of the cancer stem-cell hypothesis for breast cancer prevention and therapy. J Clin Oncol. 2008, 26: 2813-2820. 10.1200/JCO.2008.16.3931.PubMed CentralView ArticlePubMedGoogle Scholar
- Stingl J, Eaves CJ, Kuusk U, Emerman JT: Phenotypic and functional characterization in vitro of a multipotent epithelial cell present in the normal adult human breast. Differentiation. 1998, 63: 201-213. 10.1111/j.1432-0436.1998.00201.x.View ArticlePubMedGoogle Scholar
- Clayton H, Titley I, Vivanco M: Growth and differentiation of progenitor/stem cells derived from the human mammary gland. Exp Cell Res. 2004, 297: 444-460. 10.1016/j.yexcr.2004.03.029.View ArticlePubMedGoogle Scholar
- Ginestier C, Hur MH, Charafe-Jauffret E, Monville F, Dutcher J, Brown M, Jacquemier J, Viens P, Kleer CG, Liu S, et al: ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell. 2007, 1: 555-567. 10.1016/j.stem.2007.08.014.PubMed CentralView ArticlePubMedGoogle Scholar
- Smith GH, Chepko G: Mammary epithelial stem cells. Microsc Res Tech. 2001, 52: 190-203. 10.1002/1097-0029(20010115)52:2<190::AID-JEMT1005>3.0.CO;2-O.View ArticlePubMedGoogle Scholar
- Pechoux C, Gudjonsson T, Ronnov-Jessen L, Bissell MJ, Petersen OW: Human mammary luminal epithelial cells contain progenitors to myoepithelial cells. Dev Biol. 1999, 206: 88-99. 10.1006/dbio.1998.9133.View ArticlePubMedGoogle Scholar
- Stampfer MR, Bartley JC: Human mammary epithelial cells in culture: differentiation and transformation. Cancer Treat Res. 1988, 40: 1-24.View ArticlePubMedGoogle Scholar
- Dimri GP, Lee X, Basile G, Acosta M, Scott G, Roskelley C, Medrano EE, Linskens M, Rubelj I, Pereira-Smith O, et al: A biomarker that identifies senescent human cells in culture and in aging skin in vivo. Proc Natl Acad Sci USA. 1995, 92: 9363-9367. 10.1073/pnas.92.20.9363.PubMed CentralView ArticlePubMedGoogle Scholar
- Hayat M: Principles and Techniques of Electron Microscopy. 1987, London: Macmillan pressGoogle Scholar
- Blanpain C, Fuchs E: p63: revving up epithelial stem-cell potential. Nat Cell Biol. 2007, 9: 731-733. 10.1038/ncb0707-731.View ArticlePubMedGoogle Scholar
- Stingl J, Eaves CJ, Zandieh I, Emerman JT: Characterization of bipotent mammary epithelial progenitor cells in normal adult human breast tissue. Breast Cancer Res Treat. 2001, 67: 93-109. 10.1023/A:1010615124301.View ArticlePubMedGoogle Scholar
- Neumeister V, Agarwal S, Bordeaux J, Camp RL, Rimm DL: In situ identification of putative cancer stem cells by multiplexing ALDH1, CD44, and cytokeratin identifies breast cancer patients with poor prognosis. Am J Pathol. 176: 2131-2138.
- Stampfer M, Hallowes RC, Hackett AJ: Growth of normal human mammary cells in culture. In Vitro. 1980, 16: 415-425. 10.1007/BF02618365.View ArticlePubMedGoogle Scholar
- Krasna L, Dudorkinova D, Vedralova J, Vesely P, Pokorna E, Kudlackova I, Chaloupkova A, Petruzelka L, Danes J, Matouskova E: Large expansion of morphologically heterogeneous mammary epithelial cells, including the luminal phenotype, from human breast tumours. Breast Cancer Res Treat. 2002, 71: 219-235. 10.1023/A:1014457731494.View ArticlePubMedGoogle Scholar
- Ethier SP, Mahacek ML, Gullick WJ, Frank TS, Weber BL: Differential isolation of normal luminal mammary epithelial cells and breast cancer cells from primary and metastatic sites using selective media. Cancer Res. 1993, 53: 627-635.PubMedGoogle Scholar
- Brozova M, Kleibl Z, Netikova I, Sevcik J, Scholzova E, Brezinova J, Chaloupkova A, Vesely P, Dundr P, Zadinova M, et al: Establishment, growth and in vivo differentiation of a new clonal human cell line, EM-G3, derived from breast cancer progenitors. Breast Cancer Res Treat. 2007, 103: 247-257. 10.1007/s10549-006-9358-x.View ArticlePubMedGoogle Scholar
- Taylor-Papadimitriou J, Stampfer M, Bartek J, Lewis A, Boshell M, Lane EB, Leigh IM: Keratin expression in human mammary epithelial cells cultured from normal and malignant tissue: relation to in vivo phenotypes and influence of medium. J Cell Sci. 1989, 94 (Pt 3): 403-413.PubMedGoogle Scholar
- van de Vijver MJ, He YD, van't Veer LJ, Dai H, Hart AA, Voskuil DW, Schreiber GJ, Peterse JL, Roberts C, Marton MJ, et al: A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med. 2002, 347: 1999-2009. 10.1056/NEJMoa021967.View ArticlePubMedGoogle Scholar
- Gazdar AF, Kurvari V, Virmani A, Gollahon L, Sakaguchi M, Westerfield M, Kodagoda D, Stasny V, Cunningham HT, Wistuba II, et al: Characterization of paired tumor and non-tumor cell lines established from patients with breast cancer. Int J Cancer. 1998, 78: 766-774. 10.1002/(SICI)1097-0215(19981209)78:6<766::AID-IJC15>3.0.CO;2-L.View ArticlePubMedGoogle Scholar
- Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, Zhou AY, Brooks M, Reinhard F, Zhang CC, Shipitsin M, et al: The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell. 2008, 133: 704-715. 10.1016/j.cell.2008.03.027.PubMed CentralView ArticlePubMedGoogle Scholar
- Bentires-Alj M, Clarke RB, Jonkers J, Smalley M, Stein T: It's all in the details: methods in breast development and cancer. Breast Cancer Res. 2009, 11: 305-10.1186/bcr2346.PubMed CentralView ArticlePubMedGoogle Scholar
- Moll R, Krepler R, Franke WW: Complex cytokeratin polypeptide patterns observed in certain human carcinomas. Differentiation. 1983, 23: 256-269.View ArticlePubMedGoogle Scholar
- Zhou L, Jiang Y, Yan T, Di G, Shen Z, Shao Z, Lu J: The prognostic role of cancer stem cells in breast cancer: a meta-analysis of published literatures. Breast Cancer Res Treat. 122: 795-801.
- Chang B, Liu G, Xue F, Rosen DG, Xiao L, Wang X, Liu J: ALDH1 expression correlates with favorable prognosis in ovarian cancers. Mod Pathol. 2009, 22: 817-823.PubMed CentralPubMedGoogle Scholar
- Magnifico A, Albano L, Campaner S, Delia D, Castiglioni F, Gasparini P, Sozzi G, Fontanella E, Menard S, Tagliabue E: Tumor-initiating cells of HER2-positive carcinoma cell lines express the highest oncoprotein levels and are sensitive to trastuzumab. Clin Cancer Res. 2009, 15: 2010-2021. 10.1158/1078-0432.CCR-08-1327.View ArticlePubMedGoogle Scholar
- Trost TM, Lausch EU, Fees SA, Schmitt S, Enklaar T, Reutzel D, Brixel LR, Schmidtke P, Maringer M, Schiffer IB, et al: Premature senescence is a primary fail-safe mechanism of ERBB2-driven tumorigenesis in breast carcinoma cells. Cancer Res. 2005, 65: 840-849.PubMedGoogle Scholar
- Menard S, Casalini P, Campiglio M, Pupa SM, Tagliabue E: Role of HER2/neu in tumor progression and therapy. Cell Mol Life Sci. 2004, 61: 2965-2978. 10.1007/s00018-004-4277-7.View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.